Stomach cancer

AI Medical Service Inc. Signs Joint Research Agreement with US Leading Cancer Institution  

Retrieved on: 
Thursday, August 24, 2023

(hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement with Memorial Sloan Kettering Cancer Center (MSK), one of the world’s top medical research institutes on July 27, 2023.

Key Points: 
  • (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement with Memorial Sloan Kettering Cancer Center (MSK), one of the world’s top medical research institutes on July 27, 2023.
  • AIM is the first Japanese company*1 to sign a joint research agreement with MSK in the field of gastrointestinal endoscopy AI.
  • Its collaboration with MSK will facilitate joint research to investigate the application of Japanese gastrointestinal endoscopy AI in the United States.
  • Comment from CEO of AIM, Dr. Tomohiro Tada
    "I am very pleased that we have established a joint research agreement with Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading cancer research centers.

Additional Funding Awarded to Howard University Researcher to Enhance Effectiveness of Immunotherapy in Gastric Cancer

Retrieved on: 
Wednesday, August 9, 2023

Dr. Kidane-Mulat is working to enhance the effectiveness of immunotherapy in gastric cancers, which now has a very low success rate, in the five percent range.

Key Points: 
  • Dr. Kidane-Mulat is working to enhance the effectiveness of immunotherapy in gastric cancers, which now has a very low success rate, in the five percent range.
  • The overarching goal of this study is to harness XRCC1-deficient gastroesophageal cancer cells that will likely enhance the efficacy of immunotherapy response.
  • Dr. Kidane-Mulat is examining how defective XRCC1 and targeting DNA damage response contributes to aberrant innate immune cells inflammatory response.
  • This work lays the foundation for additional in-depth preclinical studies, and for the development of novel therapeutic strategies for stomach cancer.

Napoli Shkolnik Files Class Action Lawsuit Related to Toxic Air Emissions from Medical Sterilization Plant in Memphis, Tennessee

Retrieved on: 
Thursday, August 3, 2023

Napoli Shkolnik, along with Local Counsel Wampler, Carrol, Wilson & Sanderson, PLLC, filed a Class Action lawsuit in the Shelby County, Tennessee State Court on Wednesday August 2, 2023, seeking compensation for injuries suffered by the South Memphis community due to exposure to the toxic emissions from local medical sterilization facility.

Key Points: 
  • Napoli Shkolnik, along with Local Counsel Wampler, Carrol, Wilson & Sanderson, PLLC, filed a Class Action lawsuit in the Shelby County, Tennessee State Court on Wednesday August 2, 2023, seeking compensation for injuries suffered by the South Memphis community due to exposure to the toxic emissions from local medical sterilization facility.
  • Since 1979, Sterilization Services of Tennessee—located in a dense residential area of south Memphis—has been emitting dangerous amount of Ethylene Oxide into the air.
  • Late last year, the EPA began to publish information to impacted communities—including Memphis—about the most unsafe facilities using Ethylene Oxide.
  • Even more alarmingly, these emissions were approximately 100 times higher during periods of the 1980s and continue to be a devastating public health burden on the community today.

Phil and RedHill Biopharma Partner to Increase Access to Talicia®

Retrieved on: 
Thursday, July 6, 2023

Phil Inc. , a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform.

Key Points: 
  • Phil Inc. , a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform.
  • The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting the moment the physician writes a prescription.
  • The partnership between Phil and RedHill enables patients to receive Talicia® prescriptions quickly, easily, and affordably.
  • Our partnership with Phil will elevate our ability to eliminate access barriers to Talicia®,” said Ben Sloan, VP of Market Access at RedHill.

REAL MUSHROOMS Wins Best Medicinal Mushroom Product for Its Turkey Tail Mushroom Powder and Capsules

Retrieved on: 
Tuesday, June 27, 2023

NEW YORK, June 27, 2023 /PRNewswire/ -- REAL MUSHROOMS, an industry-leading supplier of premium mushroom supplements, was recognized today by Optimal Performance Living for offering the Best Medicinal Mushroom Product in the marketplace for mushroom supplements. Unlike most brands that contain grains, additives, and fillers, award-winning REAL MUSHROOMS supplements are made with only 100% real mushrooms, delivering pure mushroom extracts -- making its turkey tail powder a more authentic and potent alternative to better-known competitor brands. [See full press release]

Key Points: 
  • Optimal Performance Living has honored REAL MUSHROOMS' Turkey Tail Mushroom Extract Powder and Capsules with its Best Medicinal Mushroom Product award.
  • In an increasingly competitive marketplace for medicinal mushrooms, this award-winning company offers its customers an exceptional product for those seeking to strengthen their immune systems by harnessing the renowned power of turkey tail mushrooms.
  • NEW YORK, June 27, 2023 /PRNewswire/ -- REAL MUSHROOMS , an industry-leading supplier of premium mushroom supplements, was recognized today by Optimal Performance Living for offering the Best Medicinal Mushroom Product in the marketplace for mushroom supplements.
  • Unlike most brands that contain grains, additives, and fillers, award-winning REAL MUSHROOMS supplements are made with only 100% real mushrooms, delivering pure mushroom extracts -- making its turkey tail powder a more authentic and potent alternative to better-known competitor brands.

Sojitz Signs Memorandum of Understanding for Strategic Alliance with HIROTSU Bioscience, WHO Foundation, OurCrowd and Global Health Equity Fund

Retrieved on: 
Thursday, June 15, 2023

N-NOSE® is a simple, inexpensive, highly accurate, and comprehensive systemic cancer screening test that can be used to detect early-stage cancer simply by submitting urine.

Key Points: 
  • N-NOSE® is a simple, inexpensive, highly accurate, and comprehensive systemic cancer screening test that can be used to detect early-stage cancer simply by submitting urine.
  • Sojitz and HIROTSU concluded a capital and business alliance agreement in February 2022 and have been promoting the international development of N-NOSE® under a mutual cooperation.
  • GHEF is a unique financial-first impact venture capital investment fund, focusing on breakthrough technology solutions that can impact healthcare globally.
  • Launched by OurCrowd and the WHO Foundation, GHEF aims for impact on health equity.

Global Doxorubicin Market Report 2023: Growing Demand for Effective Cancer Treatments Fuels the Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 8, 2023

The "Global Doxorubicin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Doxorubicin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global doxorubicin market size attained a value of USD 1218 million in 2022.
  • [Doxorubicin is used primarily in the treatment of a wide range of cancers, including breast cancer, ovarian cancer, lung cancer, stomach cancer, thyroid cancer, bladder cancer, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphomas.
  • The global market for doxorubicin is expected to continue to grow in the coming years, driven by an increasing incidence of cancer and a growing demand for effective treatments.

Astellas Submits New Drug Application for Zolbetuximab in Japan

Retrieved on: 
Friday, June 9, 2023

TOKYO, June 9, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) on June 9, 2023 to Japan's Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in Japan for these patients.

Key Points: 
  • If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in Japan for these patients.
  • "Astellas' submission of a New Drug Application to Japan's Ministry of Health, Labour and Welfare for zolbetuximab demonstrates critical momentum in addressing the unmet needs of patients with gastric cancer in Japan."
  • The SPOTLIGHT study evaluated zolbetuximab plus mFOLFOX6 (a combination regimen that includes oxaliplatin, leucovorin and fluorouracil) compared to placebo plus mFOLFOX6.
  • The GLOW study evaluated zolbetuximab plus CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin) compared to placebo plus CAPOX.

Virtual, Inc. Joins Forces with Dana-Farber Cancer Institute and the Jimmy Fund to Strike Out Cancer

Retrieved on: 
Thursday, June 1, 2023

Virtual, Inc. , a leading provider of professional services to standards organizations, consortia and associations, proudly announces its continued support and commitment to Dana-Farber Cancer Institute and the Jimmy Fund.

Key Points: 
  • Virtual, Inc. , a leading provider of professional services to standards organizations, consortia and associations, proudly announces its continued support and commitment to Dana-Farber Cancer Institute and the Jimmy Fund.
  • As a Major Sponsor of Jimmy Fund Day at Fenway presented by DraftKings on June 10, Virtual’s support will help the organization’s critical mission of eradicating cancer for adults and children.
  • View the full release here: https://www.businesswire.com/news/home/20230601005116/en/
    Virtual, Inc. proudly announces its continued support and commitment to Dana-Farber Cancer Institute and the Jimmy Fund as a Major Sponsor of Jimmy Fund Day at Fenway presented by DraftKings on June 10.
  • In 2009, Virtual's CEO Andy Freed was diagnosed with metastatic thyroid cancer, and thanks to the exceptional care at Dana-Farber Cancer Institute, he remains cancer-free to this day.

Debbie's Dream Foundation: Curing Stomach Cancer Joins the 15th Annual International Gastric Cancer Congress in Japan for Patient Advocacy Session

Retrieved on: 
Thursday, May 4, 2023

FORT LAUDERDALE, Fla., May 4, 2023 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is joining forces with the International Gastric Cancer Association for the 15th Annual International Gastric Cancer Congress (IGCC). DDF patient advocates will participate in the Patient Advocacy Session on Saturday, June 17, 2023, from 8 a.m. to 12 p.m. JST, from Yokohama, Japan. The half-day session will be live-cast in North America on Friday, June 16, 2023, at 7 p.m. EST, in Europe on Saturday, June 17, 2023, at 1 a.m., and in the United Kingdom on Saturday, June 17, 2023, at 12 a.m. It will feature various panel discussions and presentations highlighting patient advocacy programs, services, and resources to oncologists and aims to provide accurate information to patients and ensure that their views are reflected in their healthcare decision-making. The entire program will be simultaneously translated into different languages, including English, Japanese, Chinese, and Korean.

Key Points: 
  • FORT LAUDERDALE, Fla., May 4, 2023 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is joining forces with the International Gastric Cancer Association for the 15th Annual International Gastric Cancer Congress (IGCC).
  • DDF patient advocates will participate in the Patient Advocacy Session on Saturday, June 17, 2023, from 8 a.m. to 12 p.m. JST, from Yokohama, Japan.
  • "DDF is proud to partner with the 15th Annual IGCC in Japan to help bring patient advocacy to the forefront," said Andrea Eidelman, Chief Executive Officer of DDF.
  • The IGCC 2023 Advocacy Session is supported in part by DDF, My Gut Feeling of Canada, and KIBOUNOKAI of Japan.